• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Programmed cell death protein-1 inhibitor for the treatment of hepatocellular carcinoma: "A sharp sword".

作者信息

Li Xin, Liang Ping, Ye Xin

机构信息

Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China.

Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China.

出版信息

J Cancer Res Ther. 2019;15(2):267-268. doi: 10.4103/jcrt.JCRT_910_18.

DOI:10.4103/jcrt.JCRT_910_18
PMID:30964095
Abstract
摘要

相似文献

1
Programmed cell death protein-1 inhibitor for the treatment of hepatocellular carcinoma: "A sharp sword".用于治疗肝细胞癌的程序性细胞死亡蛋白-1抑制剂：“一把利剑”
J Cancer Res Ther. 2019;15(2):267-268. doi: 10.4103/jcrt.JCRT_910_18.
2
Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?肿瘤相关调节性T细胞缺失与PD-1/PD-L1阻断联合应用：肝细胞癌一种有前景的免疫疗法？
Hepatobiliary Pancreat Dis Int. 2018 Apr;17(2):93-94. doi: 10.1016/j.hbpd.2018.03.001. Epub 2018 Mar 8.
3
Acute exacerbation of asthma induced by combined therapy of programmed death-1 Blocker plus lenvatinib in a patient with advanced hepatocellular carcinoma.程序性死亡-1阻断剂联合乐伐替尼治疗晚期肝细胞癌患者诱发哮喘急性加重
Eur J Cancer. 2021 Oct;156:122-124. doi: 10.1016/j.ejca.2021.07.025. Epub 2021 Aug 21.
4
The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma.在治疗黑色素瘤和肾癌的关键研究中，单独使用抗程序性死亡蛋白1（anti-PD-1）药物时加用抗细胞毒性T淋巴细胞相关蛋白4（anti-CTL-4）的临床附加值存在疑问，且毒性明显增加。
Cancer Chemother Pharmacol. 2019 May;83(5):1003-1005. doi: 10.1007/s00280-019-03804-7. Epub 2019 Mar 4.
5
Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma.免疫与肝癌术前免疫治疗病理完全缓解的相关性研究。
Cancer Immunol Res. 2019 Sep;7(9):1390-1395. doi: 10.1158/2326-6066.CIR-18-0605. Epub 2019 Jul 9.
6
On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?OX40 和 PD-1 联合治疗：为什么 OX40 应优先使用？
Clin Cancer Res. 2017 Oct 15;23(20):5999-6001. doi: 10.1158/1078-0432.CCR-17-2332.
7
A novel immunosuppression-based classification of liver tumors opens new perspectives for adapted therapeutic strategies.一种基于免疫抑制的肝脏肿瘤新分类为适应性治疗策略开辟了新视角。
EBioMedicine. 2020 Apr;54:102737. doi: 10.1016/j.ebiom.2020.102737. Epub 2020 Apr 5.
8
Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.患者肝癌对纳武利尤单抗发生超敏反应后，使用帕博利珠单抗治疗。
Am J Health Syst Pharm. 2019 Oct 15;76(21):1749-1752. doi: 10.1093/ajhp/zxz189.
9
Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma.程序性细胞死亡蛋白-1（PD-1）抑制剂单药治疗晚期肝细胞癌患者的前景黯然失色。
Biosci Trends. 2019;13(3):282-283. doi: 10.5582/bst.2019.01161.
10
Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation.用于肝移植后肝细胞癌复发的免疫检查点抑制剂。
Hepatobiliary Pancreat Dis Int. 2020 Feb;19(1):91-93. doi: 10.1016/j.hbpd.2019.09.011. Epub 2019 Oct 25.

引用本文的文献

1
Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study.微波消融联合阿帕替尼和卡瑞利珠单抗治疗晚期肝细胞癌的单臂初步研究。
Front Immunol. 2022 Oct 26;13:1023983. doi: 10.3389/fimmu.2022.1023983. eCollection 2022.
2
Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development.局部区域联合全身治疗晚期肝细胞癌：快速发展的必然趋势
Front Mol Biosci. 2021 Apr 13;8:635243. doi: 10.3389/fmolb.2021.635243. eCollection 2021.